STADA Arzneimittel Aktiengesellschaft Sustainability Profile
STADA Arzneimittel Aktiengesellschaft, commonly known as STADA, is a prominent player in the global pharmaceutical industry, headquartered in Bad Vilbel, Germany. Founded in 1895, the company has established a strong presence in Europe and beyond, focusing on the development, manufacturing, and marketing of generic and over-the-counter (OTC) products. STADA's core offerings include a diverse range of pharmaceuticals, particularly in the fields of pain management, dermatology, and respiratory health. The company is recognised for its commitment to quality and innovation, which has positioned it as a trusted provider in the healthcare sector. With a robust portfolio and a strategic focus on expanding its market reach, STADA continues to achieve significant milestones, reinforcing its status as a leader in the pharmaceutical landscape.
DitchCarbon Score
How does STADA Arzneimittel Aktiengesellschaft's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
STADA Arzneimittel Aktiengesellschaft's score of 57 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
STADA Arzneimittel Aktiengesellschaft's reported carbon emissions
In 2024, STADA Arzneimittel Aktiengesellschaft reported total carbon emissions of approximately 40923100 kg CO2e for Scope 1 and about 29853600 kg CO2e for Scope 2. The combined emissions for Scope 1 and 2 amounted to around 70776700 kg CO2e. Scope 3 emissions were significantly higher, totalling about 680611000 kg CO2e, with the largest contributions from purchased goods and services (approximately 598516000 kg CO2e) and upstream transportation and distribution (about 35163000 kg CO2e). STADA has set ambitious climate commitments, aiming to reduce its absolute greenhouse gas emissions (Scope 1 and 2) by 42% by 2030, using 2020 figures as a baseline. This target aligns with the 1.5°C global warming target and reflects the company's commitment to sustainability. As of 2024, STADA has achieved a reduction of 33.7% in its Scope 1 emissions, demonstrating progress towards its goals. The emissions data is cascaded from STADA Arzneimittel Aktiengesellschaft, which is committed to transparency and accountability in its climate initiatives. The company is actively working towards its reduction targets while addressing the significant impact of its Scope 3 emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 31,639,700 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 75,032,800 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 |
How Carbon Intensive is STADA Arzneimittel Aktiengesellschaft's Industry?
How Carbon Intensive is STADA Arzneimittel Aktiengesellschaft's Location?
STADA Arzneimittel Aktiengesellschaft's Scope 3 Categories Breakdown
STADA Arzneimittel Aktiengesellschaft's Scope 3 emissions, which increased by 1% last year and increased by approximately 1% since 2023, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 88% of Scope 3 emissions.
Top Scope 3 Categories
STADA Arzneimittel Aktiengesellschaft's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
STADA Arzneimittel Aktiengesellschaft has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about STADA Arzneimittel Aktiengesellschaft's sustainability data and climate commitments